Cancer

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for the Treatment of Dystrophic Epidermolysis...

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting

RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency...

Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) --...

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in ChinaSAN FRANCISCO and...

error: Content is protected !!